BK virus capsid antibodies are associated with protection against subsequent development of PML in HIV-infected patients

Virology

Volumn 485, Issue , 2015, Pages 467-472

  Rossi, Francesca ^a   Li, Xiuhong ^b   Jacobson, Lisa ^b   Levine, Andrew J ^c   Chen, Yue ^d   Palella, Frank J ^e   Margolick, Joseph ^b   Viscidi, Raphael ^f  

^a SAPIENZA UNIVERSITY OF ROME   (Italy)

^b JOHNS HOPKINS BLOOMBERG SCHOOL OF PUBLIC HEALTH   (United States)

^c UNIVERSITY OF CALIFORNIA   (United States)

^d UNIVERSITY OF PITTSBURGH GRADUATE SCHOOL OF PUBLIC HEALTH   (United States)

^e NORTHWESTERN UNIVERSITY   (United States)

^f JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

BK polyomavirus; Cohort study; Human immunodeficiency virus; JC polyomavirus; Progressive multifocal leukoencephalopathy; Viral serology

Indexed keywords

VIRUS ANTIBODY; IMMUNOGLOBULIN G;

ADULT; ANTIBODY TITER; ARTICLE; BK VIRUS INFECTION; BLOOD SAMPLING; CASE CONTROL STUDY; CLINICAL ARTICLE; CONTROLLED STUDY; ENZYME LINKED IMMUNOSORBENT ASSAY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; INFECTION PREVENTION; INFECTION RISK; JC VIRUS; MALE; PRIORITY JOURNAL; PROGRESSIVE MULTIFOCAL LEUKOENCEPHALOPATHY; RISK REDUCTION; SEROTYPE; VIRUS CAPSID; BK VIRUS; BLOOD; CLASSIFICATION; CROSS PROTECTION; FEMALE; IMMUNOLOGY; LEUKOENCEPHALOPATHY, PROGRESSIVE MULTIFOCAL; MIDDLE AGED; MIXED INFECTION; ODDS RATIO; RISK FACTOR;

ADULT; ANTIBODIES, VIRAL; BK VIRUS; CAPSID; CASE-CONTROL STUDIES; COINFECTION; CROSS PROTECTION; FEMALE; HIV INFECTIONS; HUMANS; IMMUNOGLOBULIN G; JC VIRUS; LEUKOENCEPHALOPATHY, PROGRESSIVE MULTIFOCAL; MALE; MIDDLE AGED; ODDS RATIO; RISK FACTORS; SEROGROUP;

EID: 84941116614     PISSN: 00426822     EISSN: 10960341     Source Type: Journal    
DOI: 10.1016/j.virol.2015.08.022     Document Type: Article

References (27)

1. Bennett S.M., Broekema N.M., Imperiale M.J. BK polyomavirus: emerging pathogen. Microbes Infect. 2012, 14:672-683.
2. Biogen Idec, 2015. Biogen Idec website. Ref Type: Online Source.
3. Bloomgren G., Richman S., Hotermans C., Subramanyam M., Goelz S., Natarajan A., Lee S., Plavina T., Scanlon J.V., Sandrock A., Bozic C. Risk of natalizumab-associated progressive multifocal leukoencephalopathy. N. Engl. J. Med. 2012, 366:1870-1880.
4. Brew B.J., Davies N.W., Cinque P., Clifford D.B., Nath A. Progressive multifocal leukoencephalopathy and other forms of JC virus disease. Nat. Rev. Neurol. 2010, 6:667-679.
5. Bright R.K., Shearer M.H., Kennedy R.C. Immunization of BALB/c mice with recombinant simian virus 40 large tumor antigen induces antibody-dependent cell-mediated cytotoxicity against simian virus 40-transformed cells. An antibody-based mechanism for tumor immunity. J. Immunol. 1994, 153:2064-2071.
6. Cheng X.S., Bohl D.L., Storch G.A., Ryschkewitsch C., Gaudreault-Keener M., Major E.O., Randhawa P., Hardinger K.L., Brennan D.C. Inhibitory interactions between BK and JC virus among kidney transplant recipients. J. Am. Soc. Nephrol. 2011, 22:825-831.
7. Christensen K.L., Holman R.C., Hammett T.A., Belay E.D., Schonberger L.B. Progressive multifocal leukoencephalopathy deaths in the USA, 1979-2005. Neuroepidemiology 2010, 35:178-184.
8. Cinque P., Koralnik I.J., Gerevini S., Miro J.M., Price R.W. Progressive multifocal leukoencephalopathy in HIV-1 infection. Lancet Infect. Dis. 2009, 9:625-636.
9. Detels R., Jacobson L., Margolick J., Martinez-Maza O., Munoz A., Phair J., Rinaldo C., Wolinsky S. The multicenter AIDS Cohort Study, 1983 to . .. Public Health 2012, 126:196-198.
10. Du Pasquier R.A., Kuroda M.J., Zheng Y., Jean-Jacques J., Letvin N.L., Koralnik I.J. A prospective study demonstrates an association between JC virus-specific cytotoxic T lymphocytes and the early control of progressive multifocal leukoencephalopathy. Brain 2004, 127:1970-1978.
11. Egli A., Infanti L., Dumoulin A., Buser A., Samaridis J., Stebler C., Gosert R., Hirsch H.H. Prevalence of polyomavirus BK and JC infection and replication in 400 healthy blood donors. J. Infect. Dis. 2009, 199:837-846.
12. Gorelik L., Lerner M., Bixler S., Crossman M., Schlain B., Simon K., Pace A., Cheung A., Chen L.L., Berman M., Zein F., Wilson E., Yednock T., Sandrock A., Goelz S.E., Subramanyam M. Anti-JC virus antibodies: implications for PML risk stratification. Ann. Neurol. 2010, 68:295-303.
13. Hamilton R.S., Gravell M., Major E.O. Comparison of antibody titers determined by hemagglutination inhibition and enzyme immunoassay for JC virus and BK virus. J. Clin. Microbiol. 2000, 38:105-109.
14. Kean J.M., Rao S., Wang M., Garcea R.L. Seroepidemiology of human polyomaviruses. PLoS Pathog. 2009, 5:e1000363.
15. Khanna N., Wolbers M., Mueller N.J., Garzoni C., Du Pasquier R.A., Fux C.A., Vernazza P., Bernasconi E., Viscidi R., Battegay M., Hirsch H.H. JC virus-specific immune responses in human immunodeficiency virus type 1 patients with progressive multifocal leukoencephalopathy. J. Virol. 2009, 83:4404-4411.
16. Knowles W.A., Pipkin P., Andrews N., Vyse A., Minor P., Brown D.W., Miller E. Population-based study of antibody to the human polyomaviruses BKV and JCV and the simian polyomavirus SV40. J. Med. Virol. 2003, 71:115-123.
17. Kornek B. An update on the use of natalizumab in the treatment of multiple sclerosis: appropriate patient selection and special considerations. Patient Preference Adherence 2015, 9:675-684.
18. Li J., Melenhorst J., Hensel N., Rezvani K., Sconocchia G., Kilical Y., Hou J., Curfman B., Major E., Barrett A.J. T-cell responses to peptide fragments of the BK virus T antigen: implications for cross-reactivity of immune response to JC virus. J. Gen. Virol. 2006, 87:2951-2960.
19. Pastrana D.V., Ray U., Magaldi T.G., Schowalter R.M., Cuburu N., Buck C.B. BK polyomavirus genotypes represent distinct serotypes with distinct entry tropism. J. Virol. 2013, 87:10105-10113.
20. Plavina T., Subramanyam M., Bloomgren G., Richman S., Pace A., Lee S., Schlain B., Campagnolo D., Belachew S., Ticho B. Anti-JC virus antibody levels in serum or plasma further define risk of natalizumab-associated progressive multifocal leukoencephalopathy. Ann. Neurol. 2014, 76:802-812.
21. Rossi A.P., Anderson K.L., Brennan D.C. JC polyoma virus and kidney disease. Kidney Int. 2014, 85:1242.
22. Rossi F., Newsome S.D., Viscidi R. Molecular diagnostic tests to predict the risk of progressive multifocal leukoencephalopathy in natalizumab-treated multiple sclerosis patients. Mol. Cell. Probes 2015, 29:54-62.
23. Viscidi R.P., Shah K.V. Polyomaviurses. Infectious Diseases 2010, 1570-1572. Mosby Elsevier, Edinburgh. J. Cohen, S.M. Opal, W.G. Powderly (Eds.).
24. Viscidi R.P., Clayman B. Serological cross reactivity between polyomavirus capsids. Adv. Exp. Med. Biol. 2006, 577:73-84.
25. Viscidi R.P., Khanna N., Tan C.S., Li X., Jacobson L., Clifford D.B., Nath A., Margolick J.B., Shah K.V., Hirsch H.H., Koralnik I.J. JC virus antibody and viremia as predictors of progressive multifocal leukoencephalopathy in human immunodeficiency virus-1-infected individuals. Clin. Infect. Dis. 2011, 53:711-715.
26. Viscidi R.P., Rollison D.E., Sondak V.K., Silver B., Messina J.L., Giuliano A.R., Fulp W., Ajidahun A., Rivanera D. Age-specific seroprevalence of Merkel cell polyomavirus, BK virus, and JC virus. Clin. Vaccine Immunol. 2011, 18:1737-1743.
27. Viscidi R.P., Rollison D.E., Viscidi E., Clayman B., Rubalcaba E., Daniel R., Major E.O., Shah K.V. Serological cross-reactivities between antibodies to simian virus 40, BK virus, and JC virus assessed by virus-like-particle-based enzyme immunoassays. Clin. Diagn. Lab. Immunol. 2003, 10:278-285.